Indicators
Indicators
Value
Direction
MACD(12,26,9)
-1.078
Neutral
RSI(14)
83.396
Overbought
STOCH(KDJ)(9,3,3)
74.734
Neutral
ATR(14)
0.565
High Vlolatility
CCI(14)
89.812
Neutral
Williams %R
22.596
Buy
TRIX(12,20)
1.572
Sell
StochRSI(14)
0.000
Sell
Mersana Therapeutics Inc
MRSN28.920USD
-0.020-0.07%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
144.56MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Mersana Therapeutics Inc
Currency: USD Updated: 2025-12-22Key Insights
Mersana Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 102/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 33.20.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Mersana Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Hold
Current Rating
33.200
Target Price
+18.91%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Mersana Therapeutics Inc Highlights
StrengthsRisks
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 52.35% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 40.50M.
Undervalued
The company’s latest PE is -2.06, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.05M shares, decreasing 46.26% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 88.47K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.96.
Financial Health
Currency: USD Updated: 2025-12-22The current financial score of Mersana Therapeutics Inc is 7.76, ranking 86/404 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 11.01M, representing a year-over-year decrease of 12.61%, while its net profit experienced a year-over-year decrease of 34.40%.
Score
Financials
6.38
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.14
Operational Efficiency
10.00
Growth Potential
7.96
Shareholder Returns
7.30
Mersana Therapeutics Inc's Company Valuation
Currency: USD Updated: 2025-12-22The current valuation score of Mersana Therapeutics Inc is 7.29, ranking 147/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.06, which is -99.15% below the recent high of -0.02 and -0.62% above the recent low of -2.07.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 102/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-22The current earnings forecast score of Mersana Therapeutics Inc is 6.25, ranking 345/404 in the Biotechnology & Medical Research industry. The average price target for Mersana Therapeutics Inc is 29.00, with a high of 50.00 and a low of 27.25.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
8
analysts
Hold
Current Rating
33.200
Target Price
+18.91%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Mersana Therapeutics Inc
MRSN
8
CRISPR Therapeutics AG
CRSP
30
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
argenx SE
ARGX
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-22The current price momentum score of Mersana Therapeutics Inc is 8.31, ranking 106/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 29.82 and the support level at 27.58, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
29.013
Sell
MA10
28.648
Buy
MA20
28.111
Buy
MA50
19.476
Buy
MA100
13.442
Buy
MA200
11.219
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-22The current institutional shareholding score of Mersana Therapeutics Inc is 5.00, ranking 146/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 61.05%, representing a quarter-over-quarter decrease of 14.87%. The largest institutional shareholder is The Vanguard, holding a total of 302.55K shares, representing 6.05% of shares outstanding, with 9.96% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Nextech Invest, Ltd.
Bain Capital Life Sciences Investors, LLC
Schonfeld Strategic Advisors LLC
683 Capital Management LLC
Rock Springs Capital Management LP
Acadian Asset Management LLC
SilverArc Capital Management, LLC
BlackRock Institutional Trust Company, N.A.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-22The current risk assessment score of Mersana Therapeutics Inc is 2.75, ranking 211/404 in the Biotechnology & Medical Research industry. The company's beta value is 0.42. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.42
VaR
+8.64%
240-Day Maximum Drawdown
+80.92%
240-Day Volatility
+362.32%
Return
Best Daily Return
60 days
+209.24%
120 days
+209.24%
5 years
+209.24%
Worst Daily Return
60 days
-13.56%
120 days
-20.59%
5 years
-72.63%
Sharpe Ratio
60 days
+2.32
120 days
+1.70
5 years
+0.18
Risk Assessment
Maximum Drawdown
240 days
+80.92%
3 years
+97.26%
5 years
+98.56%
Return-to-Drawdown Ratio
240 days
+24.85
3 years
+1.18
5 years
+0.12
Skewness
240 days
+10.89
3 years
+9.83
5 years
+10.32
Volatility
Realised Volatility
240 days
+362.32%
5 years
+197.04%
Standardised True Range
240 days
+1.87%
5 years
+1.47%
Downside Risk-Adjusted Return
120 days
+880.79%
240 days
+880.79%
Maximum Daily Upside Volatility
60 days
+441.66%
Maximum Daily Downside Volatility
60 days
+416.65%
Liquidity
Average Turnover Rate
60 days
+1.42%
120 days
+1.89%
5 years
--
Turnover Deviation
20 days
-96.15%
60 days
-27.49%
120 days
-3.66%
Peer Comparison
Biotechnology & Medical Research
Mersana Therapeutics Inc
MRSN
6.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Mersana Therapeutics Inc?
The TradingKey Stock Score provides a comprehensive assessment of Mersana Therapeutics Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Mersana Therapeutics Inc’s performance and outlook.
How do we generate the financial health score of Mersana Therapeutics Inc?
To generate the financial health score of Mersana Therapeutics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Mersana Therapeutics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Mersana Therapeutics Inc.
How do we generate the company valuation score of Mersana Therapeutics Inc?
To generate the company valuation score of Mersana Therapeutics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Mersana Therapeutics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Mersana Therapeutics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Mersana Therapeutics Inc.
How do we generate the earnings forecast score of Mersana Therapeutics Inc?
To calculate the earnings forecast score of Mersana Therapeutics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Mersana Therapeutics Inc’s future.
How do we generate the price momentum score of Mersana Therapeutics Inc?
When generating the price momentum score for Mersana Therapeutics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Mersana Therapeutics Inc’s prices. A higher score indicates a more stable short-term price trend for Mersana Therapeutics Inc.
How do we generate the institutional confidence score of Mersana Therapeutics Inc?
To generate the institutional confidence score of Mersana Therapeutics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Mersana Therapeutics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Mersana Therapeutics Inc.
How do we generate the risk management score of Mersana Therapeutics Inc?
To assess the risk management score of Mersana Therapeutics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Mersana Therapeutics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Mersana Therapeutics Inc.
